Education
About Us
Working with TipRanks
Follow Us
Annovis Bio Inc (ANVS)
:ANVS
ANVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.11 - $20.00
Previous CloseN/A
Volume368.97K
Average Volume (3M)241.51K
Market Cap
$24.55M
Enterprise Value$58.83M
Total Cash (Recent Filing)$10.55M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.49
Next Earnings
May 08, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding19,486,230
10 Day Avg. Volume203,814
30 Day Avg. Volume241,513
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap2.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$8.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Annovis Bio News
PremiumCompany Announcements
Annovis Bio Faces NYSE Non-Compliance Notice
PremiumCompany Announcements
Annovis Bio Launches Phase 3 Alzheimer’s Study---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentAnnovis Bio, Inc. is set to conduct a pivotal Phase 3 study for Buntanetap in Alzheimer's Disease.
Market ValuationThe stock is viewed as significantly undervalued from a longer-term perspective, due to the high unmet need in Alzheimer's disease and the large potential market.
Regulatory ApprovalsThe FDA granted clearance to Annovis Bio to proceed with pivotal Phase 3 studies of its lead candidate buntanetap.
Bears Say
Financing ChallengesSuccessfully navigating through funding needs remains very important to execute on its plans.
Market ConditionsBroad market headwinds continue including challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.
Stock Price TargetFactoring in dilution from the financing lowers the 12-month price target to $8, from $25.
---
Ownership Overview
14.30% Insiders
2.96% Mutual Funds
0.60% Other Institutional Investors
78.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANVS FAQ
What was Annovis Bio Inc’s price range in the past 12 months?
Annovis Bio Inc lowest stock price was $1.11 and its highest was $20.00 in the past 12 months.
What is Annovis Bio Inc’s market cap?
Annovis Bio Inc’s market cap is $24.55M.
When is Annovis Bio Inc’s upcoming earnings report date?
Annovis Bio Inc’s upcoming earnings report date is May 08, 2025 which is in 19 days.
How were Annovis Bio Inc’s earnings last quarter?
Annovis Bio Inc released its earnings results on Apr 08, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$0.02.
Is Annovis Bio Inc overvalued?
According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued.
Does Annovis Bio Inc pay dividends?
Annovis Bio Inc does not currently pay dividends.
What is Annovis Bio Inc’s EPS estimate?
Annovis Bio Inc’s EPS estimate is -0.41.
How many shares outstanding does Annovis Bio Inc have?
Annovis Bio Inc has 19,486,230 shares outstanding.
What happened to Annovis Bio Inc’s price movement after its last earnings report?
Annovis Bio Inc reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of Annovis Bio Inc?
Currently, no hedge funds are holding shares in ANVS
---
Annovis Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (534.92% Upside)
$8.00 (534.92% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.42%
12-Months-Change
Fundamentals
Return on Equity
-3159.09%
Trailing 12-Months
Asset Growth
36.42%
Trailing 12-Months
Company Description
Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
---
ANVS Stock 12 Month Forecast
Average Price Target
$8.00
▲(534.92% Upside)
Technical Analysis
Best Analysts Covering ANVS
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-62.77%
reiterated a buy rating 5 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -62.77% per trade.
---